Enliven Therapeutics's total assets for Q1 2025 were $302.57M, a decrease of -7.12% from the previous quarter. ELVN total liabilities were $14.27M for the fiscal quarter, a -10.31% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.